Lung Cancer | Topics

 
Nivolumab Plus Ipilimumab Demonstrate Continued Survival Benefit in All Subgroups in Unresectable Malignant Pleural Mesothelioma
September 18, 2021

Findings from the phase 3 CheckMate 743 trial indicated that patients with unresectable malignant pleural mesothelioma derived a continued overall survival benefit after being treated with nivolumab and ipilimumab.

Mobocertinib Plus T-DM1 Combo Shows Efficacy in HER2 Exon 20 Insertion–Mutant Lung Cancer Cell Lines
September 13, 2021

With the combination of mobocertinib and T-DM1, potent preclinical efficacy was observed in lung cancer cells with HER2 exon 20 insertion mutations.

Alexander Spira, MD, PhD, FACP, Discusses Biomarker-Guided Treatment in Lung Cancer at 2021 WCLC
September 10, 2021

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about KRAS as a therapy biomarker in lung cancer.